56.08 USD
+0.88 (+1.59%)
56.08 USD
0 (0%)
Overall BMRN gets a fundamental rating of 6 out of 10. We evaluated BMRN against 528 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes BMRN very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
- BMRN had positive earnings in the past year.
- BMRN had a positive operating cash flow in the past year.
- BMRN had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
- BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.61% of its industry peers.
- With an excellent Return On Equity value of 8.59%, BMRN belongs to the best of the industry, outperforming 92.05% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 7.69%, BMRN belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 18.28%.
- The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
- BMRN's Profit Margin of 16.82% is amongst the best of the industry. BMRN outperforms 92.61% of its industry peers.
- The Operating Margin of BMRN (20.21%) is better than 94.51% of its industry peers.
- Looking at the Gross Margin, with a value of 81.32%, BMRN belongs to the top of the industry, outperforming 85.23% of the companies in the same industry.
- In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
- The number of shares outstanding for BMRN has been increased compared to 1 year ago.
- The number of shares outstanding for BMRN has been increased compared to 5 years ago.
- Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
- BMRN has an Altman-Z score of 5.28. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
- With a decent Altman-Z score value of 5.28, BMRN is doing good in the industry, outperforming 73.30% of the companies in the same industry.
- The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
- BMRN has a Debt to FCF ratio of 0.72. This is amongst the best in the industry. BMRN outperforms 94.51% of its industry peers.
- BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of BMRN (0.10) is worse than 62.50% of its industry peers.
- Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.28 |
ROIC/WACC0.92
WACC8.33%
2.3 Liquidity
- BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
- BMRN has a Current ratio of 4.83. This is comparable to the rest of the industry: BMRN outperforms 55.87% of its industry peers.
- A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.10, BMRN is doing worse than 60.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 52.00% over the past year.
- Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
- The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
- Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
- The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y28.19%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.22%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- BMRN is valuated rather expensively with a Price/Earnings ratio of 21.08.
- BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.51% of the companies in the same industry.
- BMRN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.33, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 12.45, which indicates a correct valuation of BMRN.
- Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 96.97% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (24.12), we can say BMRN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.08 | ||
| Fwd PE | 12.45 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaper than 94.89% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BMRN is valued cheaper than 97.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.05 | ||
| EV/EBITDA | 13.41 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BMRN may justify a higher PE ratio.
- A more expensive valuation may be justified as BMRN's earnings are expected to grow with 35.49% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y42.79%
EPS Next 3Y35.49%
5. Dividend
5.1 Amount
- BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
56.08
+0.88 (+1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners97.82%
Inst Owner Change0.76%
Ins Owners0.64%
Ins Owner Change-0.62%
Market Cap10.77B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target92.08 (64.19%)
Short Float %4.25%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-0.96%
PT rev (3m)-5.43%
EPS NQ rev (1m)-3.95%
EPS NQ rev (3m)8.36%
EPS NY rev (1m)1.38%
EPS NY rev (3m)-14.9%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.08 | ||
| Fwd PE | 12.45 | ||
| P/S | 3.48 | ||
| P/FCF | 13.05 | ||
| P/OCF | 11.79 | ||
| P/B | 1.78 | ||
| P/tB | 1.91 | ||
| EV/EBITDA | 13.41 |
EPS(TTM)2.66
EY4.74%
EPS(NY)4.51
Fwd EY8.03%
FCF(TTM)4.3
FCFY7.67%
OCF(TTM)4.76
OCFY8.48%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.59
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.28 |
F-Score8
WACC8.33%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y41.21%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 35.7% in the next year.